Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Stage of Development | 8 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Therapy Area | 9 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Indication | 10 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Companies | 13 | 2 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Universities/Institutes | 15 | 2 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 1 |
| Assessment by Molecule Type | 21 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Companies Involved in Therapeutics Development | 22 | 6 |
| Addex Therapeutics Ltd | 22 | 1 |
| Domain Therapeutics SA | 23 | 1 |
| Eli Lilly and Company | 24 | 1 |
| Johnson &Johnson | 25 | 1 |
| Merck &Co., Inc. | 26 | 1 |
| Taisho Pharmaceutical Holdings Co., Ltd. | 27 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Drug Profiles | 28 | 11 |
| ADX-92639 Drug Profile | 28 | 1 |
| JNJ-40411813 Drug Profile | 29 | 3 |
| LSN-2535717 Drug Profile | 32 | 1 |
| LY-2607540 Drug Profile | 33 | 1 |
| MGS-0028 Drug Profile | 34 | 1 |
| Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis Drug Profile | 35 | 1 |
| Small Molecules to Antagonize mGlu2 for Anxiety and Depression Drug Profile | 36 | 1 |
| Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders Drug Profile | 37 | 1 |
| Small Molecules to Antagonize mGluR2 for Parkinson s Disease Drug Profile | 38 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Dormant Projects | 39 | 3 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Discontinued Products | 42 | 1 |
| Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Featured News &Press Releases | 43 | 10 |
| Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy | 43 | 1 |
| Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death | 43 | 1 |
| Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms | 44 | 1 |
| Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression | 44 | 1 |
| Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients | 45 | 2 |
| Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients | 47 | 1 |
| Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms | 48 | 1 |
| Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms | 48 | 1 |
| Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia | 49 | 1 |
| Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer s Disease Model | 50 | 1 |
| Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program | 51 | 1 |
| Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator | 51 | 1 |
| Jan 17, 2005: Addex Pharmaceuticals Enters Into Collaboration With Ortho-McNeil Pharmaceutical To Develop Novel Treatments For Anxiety, Depression, Schizophrenia And Alzheimer's Disease | 52 | 1 |
| Appendix | 53 | 2 |
| Methodology | 53 | 1 |
| Coverage | 53 | 1 |
| Secondary Research | 53 | 1 |
| Primary Research | 53 | 1 |
| Expert Panel Validation | 53 | 1 |
| Contact Us | 53 | 1 |
| Disclaimer | 54 | 1 |